TTLTicker Tales
NSE: DIVISLABHealthcare

Divi's Laboratories

Divi's Laboratories manufactures and exports active pharmaceutical ingredients, pharma intermediates and custom-synthesised molecules for global pharma and agrochemical companies, operating mainly as a contract development and manufacturing organisation (CDMO).

₹11,565.50▲+73.5%1 yearClosing price, 9 Nov 2026
  • P/E ~90x
  • ROE 16.5%, ROCE 22%
  • Near debt-free
  • All-time high, ₹3 lakh cr mcap
  • Zero promoter pledge

Updated on 10 Nov 2026 · Data as of 9 Nov 2026

Get this report as a PDF free, straight to your inbox.

Snapshot

Share price
₹11,565.50
9 Nov 2026
52-week range
₹5,797.09 – ₹11,565.50
All-time peak
₹11,565.50
9 Nov 2026 · 0.0% from peak
Dividend yield
0.26%
Price history since
2003
About 23 years of prices
52-week low ₹5,797.09high ₹11,565.50

What's happening

Q2 FY27 (Jul-Sep 2026) results announced in early November 2026: consolidated revenue rose 35.4% YoY to ₹3,676 crore and net profit rose 63.6% YoY to ₹1,127 crore, driven by Custom Synthesis (CDMO) sales up 44% YoY. The stock jumped roughly 15% in two sessions, hit an all-time high near ₹11,786-11,818 and took Divi's past ₹3 trillion market cap for the first time. Management guided double-digit revenue growth for H2 FY27, building on 17% constant-currency growth in H1.

In plain terms

Divi's makes the chemical building blocks and finished drug ingredients that big pharma companies outsource rather than make themselves. The results were genuinely strong - profit grew faster than revenue because higher-margin custom-manufacturing work is a bigger share of the mix now. The tension: the market has already priced in a lot of future growth - the stock trades near 90 times trailing earnings - so the real question isn't whether the business did well last quarter, it's whether this pace of growth (tied to a handful of large, named manufacturing projects reaching commercial scale) continues for several more years.

Quarters

The available quarterly data (not a fully contiguous run of eight quarters - some quarters were not retrievable and are marked 'Not verified - check on Screener' rather than guessed) shows margin expansion layered on top of revenue growth: Dec 2024 revenue ₹2,604 cr / EBITDA margin ~34.2% / PAT ₹583 cr; Mar 2025 revenue ₹2,831 cr / margin ~33.0% / PAT ₹751 cr; Jun 2025 revenue ₹3,080 cr / margin ~40.7% / PAT ₹902 cr; Sep 2025 revenue ₹2,715 cr / margin ~32.7% / PAT ₹689 cr; Sep 2026 (latest) revenue ₹3,676 cr / margin ~42.6% / PAT ₹1,127 cr. Management attributed the jump to Custom Synthesis growing ~44-50% YoY as three large dedicated projects move through validation, with one nearing commercialisation. No tax or revenue-recognition reclassification was flagged in the results - the EBITDA and PAT trends move together with revenue, so the growth looks like a genuine operating story rather than an accounting artifact.

Performance

Heads-up on splits: Divi's Laboratories has split its shares or issued bonus shares before (most recently 2-for-1 on 23 Sept 2015, 2-for-1 on 30 Jul 2009 and 5-for-1 on 3 Aug 2007). A sudden price drop around a split date is usually just the price adjusting for the extra shares, not a crash.

Share price

+73.6% over 1 year

Returns by period

PeriodDivi's LaboratoriesNifty 50LAURUSLABS
3 months+39.3%+1.9%+32.4%
1 year+73.5%−2.1%+145.5%
3 years+236.0%+28.9%+568.7%
5 years+140.8%+38.8%+408.1%

₹100 invested on 9 Nov 2021 became…

  • Divi's Laboratories₹241
  • Nifty 50₹139
  • LAURUSLABS₹508

Divi's has been listed 23.7 years and has gone through three stock splits (5:1 in 2007, 2:1 in 2009, 2:1 in 2015 - a cumulative 20x split-adjustment) but no demergers, so there is no spin-off-related understatement to correct for here. The stock is currently at its all-time high (0% drawdown from peak) after a sharp rally. Despite that, on a relative basis it has lagged its CDMO peer Laurus Labs by a wide margin over longer horizons - 1Y: 73.6% vs peer 145.5%; 3Y: 236.0% vs peer 568.7%; 5Y: 140.8% vs peer 408.1% - while comfortably beating the Nifty over all these periods. Laurus is a smaller, higher-beta stock that re-rated faster off a lower base on similar CDMO optimism; Divi's has been the steadier, larger, less volatile compounder of the two.

Dividend

Paid in the last 12 months

₹30.00 per share

Dividend yield

0.26%

Dividend yield is the last 12 months of dividends divided by today's share price. A 0.3% yield means every ₹100 of Divi's Laboratories shares paid about ₹0.3 in dividends over the past year. Past payouts can change.

Recent dividends

DatePer share
24 Jul 2026₹30.00
25 Jul 2025₹30.00
2 Aug 2024₹30.00
11 Aug 2023₹30.00
11 Aug 2022₹30.00
17 Aug 2021₹20.00
25 Feb 2020₹16.00
14 Aug 2019₹16.00

Valuation

Expensive by conventional yardsticks: ~90x trailing P/E and ~17x price-to-book against an ROE of 16.5%, among the richest multiples in Indian pharma/CDMO. Why it is priced this way: the market is paying up for the CDMO/Custom Synthesis re-acceleration (44-50% YoY segment growth), near-zero debt, 22% ROCE, and optionality around global peptide/GLP-1 outsourcing demand (analysts have flagged Divi's as a possible beneficiary of Novo Nordisk shifting some manufacturing to external partners - this is analyst commentary, not a confirmed contract, and should not be treated as booked business). Whether it is actually cheap is a separate question: at this multiple, the stock is pricing in several more years of sustained double-digit-plus growth and margin durability: any slippage in project timelines would compress the multiple as much as the earnings.

Growth

Growth right now is both volume- and margin-led: revenue is up 35% YoY and EBITDA margin has expanded from the low-to-mid 30s into the low 40s (42.6% in the latest quarter) as the higher-margin Custom Synthesis business grew to 62% of H1 sales versus 38% for Generics. That said, this growth has historically been lumpy - Screener-reported 5-year sales growth as low as ~8.7% going into this year, reflecting a period of generic API pricing pressure and project timing gaps. The current acceleration is tied to specific large dedicated projects reaching validation/commercial scale, not broad-based volume growth across the whole portfolio, so durability depends on project-by-project execution rather than market-wide demand.

Health

Financially clean: borrowings of only about ₹7 crore as of March 2026, ROCE of 22%, and FY26 operating cash flow of ₹2,738 crore against PAT - a healthy ~105% cash conversion, so profits are turning into real cash, not just accounting earnings. Free cash flow for FY26 was a much smaller ₹221 crore because the company is in a heavy capacity-expansion phase. The thing to watch here is business risk (will the new capacity and the named large projects deliver the volumes guided), not financial risk - there is no leverage or balance-sheet stress to speak of.

Ownership

The Divi promoter family has held a stable ~51.9% stake through the last four quarters with zero shares pledged. Institutional ownership is meaningful - domestic institutions around 19.2%, foreign institutions around 5.7% - with the remainder in public/other hands (third-party shareholding breakdowns found did not cleanly sum to 100%, so treat the split between public and 'other' categories as approximate - check Screener for the exact current filing). No single well-known individual investor shows up with a notable disclosed stake; this is a promoter-plus-institution-owned stock, not one associated with a marquee retail investor.

The View

The one thing to watch

Whether the three large dedicated Custom Synthesis projects currently in validation actually commercialise on the schedule management guided over the next few quarters - that determines if the current margin and growth re-acceleration (and the ~90x multiple being paid for it) is a durable step-change or a peak.

Strengths

  • +Custom Synthesis (CDMO) revenue grew ~44% YoY to about ₹2,200 crore in Q2 FY27, lifting that segment to 62% of H1 sales mix
  • +EBITDA margin expanded to 42.6% in the latest quarter from roughly 33% a year earlier as the higher-margin mix scales
  • +Virtually debt-free (~₹7 crore borrowings) with ROCE of 22% and zero promoter pledge
  • +Management has guided double-digit revenue growth for H2 FY27 after 17% constant-currency growth in H1

Watchpoints

  • !At ~90x trailing earnings and ~17x book value, the stock already prices in several more years of strong growth - any slip in the 'three large dedicated' Custom Synthesis projects' validation-to-commercialisation timeline would hit both earnings and the multiple
  • !Growth here has historically been lumpy and project-driven rather than steady - 5-year sales growth was reported as low as ~8.7% before this recent acceleration, so one strong year does not yet establish a new sustained trend
  • !Despite the recent rally to an all-time high, Divi's has materially underperformed peer Laurus Labs over 1, 3 and 5 years (e.g., 5Y: 140.8% vs 408.1%), so the re-rating here has lagged peers making similar CDMO bets
  • !The Novo Nordisk/GLP-1 outsourcing angle currently cited by some analysts as a tailwind is speculative commentary, not a signed contract - should not be treated as confirmed future revenue

How sure are we about the data? · Moderate

Q2 FY27 headline figures (revenue ~₹3,676 cr, PAT ~₹1,127 cr, growth rates, all-time-high price, ₹3 trillion market cap) were cross-checked across multiple independent sources (Business Standard, Gurufocus, MarketsMojo, Upstox, Screener) and are consistent. Could not verify a fully contiguous 8-quarter trend - gaps are marked rather than filled in. Shareholding percentages (promoter 51.88%, FII 5.71%, DII 19.17%, public 6.55%) did not sum cleanly to 100% across third-party aggregators - treat the non-promoter split as approximate and check the company's latest exchange filing. P/E was cited as ranging 80-90x depending on source and date given the fast-moving price; 89.8x (Screener, most current) was used as primary.

Keep it for later

Get the Divi's Laboratories report as a PDF

The full report, neatly laid out with charts and tables, sent to your inbox. Handy to read offline or share.

Free. We use your email only to send this report and the newsletter.

Share this X LinkedIn WhatsApp

← All Nifty 100 companies

Reports are refreshed every quarter, about three days after each company announces its results.

Ticker Tales is not a SEBI-registered investment adviser or research analyst. This report is for learning only and is not investment advice. Data as of 9 Nov 2026.